Sun Pharma bought debt-ridden pharmaceutical giant Ranbaxy for $4bn from Daiichi Sankyo.
Luthra & Luthra advised Ranbaxy and its senior management and independent directors, led by managing partner Rajiv Luthra and partners Bobby Chandiok, Sameer Dudoria, Sandeep Dudeja, Damini Bhalla and Vaibhav Kakkar.
Ranbaxy co-counsel was Amarchand Mangaldas, led by Mumbai managing partner Cyril Shroff, and partners Nivedita Rao and Gurpreet Asher, who also acted for Ranbaxy majority-owner Daiichi.
Davis Polk & Wardwell New York partner Michael Davis and associate Brian Friedman advised Daiichi and Ranbaxy as international legal counsel.
Crawford Bayley partner Sanjay Asher acted for Sun Pharma with Shearman & Sterling partner Peter Lyons.
In the all stock transaction, Sun Pharma is buying Ranbaxy equity for around $3.2bn, while Ranbaxy shareholders will get 0.8 shares in Sun Pharma for every share of Ranbaxy, reported Moneycontrol.
Daiichi owned 63.4 per cent in India’s top drug manufacturer by sales, according to Reuters, has been struck by a US export ban on its drug ingredients.
Photo by Open Knowledge Foundation
threads most popular
thread most upvoted
comment newest
first oldest
first
Ranbaxy co-counsel was Amarchand Mangaldas, led by Mumbai managing partner Cyril Shroff, and partners Nivedita Rao and Gurpreet Asher, who also acted for Ranbaxy majority-owner Daiichi.
Looks like whatever had to brew has already spilt over in that tons of people left. Looks like Big Man RKL is now back in charge and showing who, in the end, is the BOSS!
Big banker you clearly are not big enough to work with the queen ZIA. Grow up. How is the AMSS model working when partners are treated like junior associates. They get no freedom. The partners are Not allowed any press interaction or quotes . The press profile is only for family. the partners even fly cattle class. The average AMSS Pa or partner hopes for a job with AZB or Khaitan.
C..eriously.
threads most popular
thread most upvoted
comment newest
first oldest
first